Alirocumab (anti-PCSK9) | PCSK9 | Read Reviews & Product Use Citations

Alirocumab (anti-PCSK9) works by inhibiting the PCSK9 protein, which binds to the low-density lipoprotein receptor (LDLR) and causes receptor degradation, removing less LDL cholesterol from the circulation.

Click to purchase the isotype control of Alirocumab (anti-PCSK9)

Purity & Quality Control

Batch: A204701 Purity: 98% Protein concentration: 4.3mg/ml Endotoxin Level: <1 EU/mg

98

Choose Selective PCSK9 Inhibitors

Biological Activity

Description	Alirocumab (anti-PCSK9) works by inhibiting the PCSK9 protein, which binds to the low-density lipoprotein receptor (LDLR) and causes receptor degradation, removing less LDL cholesterol from the circulation.

Product Details

CAS No.	1245916-14-6
Molecular Weight	150 kDa
Isotype	human IGg1, κ
Application	Alirocumab (anti-PCSK9)
Source	CHO
Purification	Protein G
Sterility	0.2 μM filtered
Formulation	PBS Buffer, PH 7.4
Storage (From the date of receipt)	Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles

Tech Support

If you have any other enquiries, please leave a message.

* Indicates a Required Field